Dyadic (AMEX:DIL)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Dyadic Charts. Click Here for more Dyadic Charts.](/p.php?pid=staticchart&s=A%5EDIL&p=8&t=15)
Dyadic International, Inc. (AMEX:DIL), a global
biotechnology company (the "Company"), with subsidiaries in Hong Kong
and mainland China, Poland, and The Netherlands, announced today that
on April 28, 2006, it purchased the remaining 17.5% of shares held by
two minority shareholders of its Asian subsidiary, giving it 100%
ownership. The Asian subsidiary is located in Hong Kong and mainland
China, and serves as a distributor of Dyadic's products to the Far
East region. The minority shareholders received $375,000 in cash and
212,501 shares of unregistered and restricted Dyadic common stock in
consideration for:
-- the transfer of all of the minority shareholders' shares
(representing 17.5% of the Asian subsidiary's outstanding
shares) to the Company, bringing the Company's ownership in
the Asian subsidiary to 100%;
-- a release of the Company from, among other things, the
potential $405,000 contingent obligation to one of the
minority shareholders incident to the Company's purchase of
its initial majority interest in the Asian subsidiary in 1998;
and
-- the cancellation of all indebtedness of the Asian subsidiary
to the minority shareholders in the aggregate amount of
$241,854.
Mark Emalfarb, Dyadic's Chairman and CEO, commented, "Our Asian
subsidiary has been an important part of Dyadic's global business for
a number of years, and has ably served as our gateway to the Far East.
The Asian subsidiary team, now 74 people strong, provided
approximately 40% of our 2005 revenues and has done a particularly
outstanding job in helping us to establish a toe-hold in the pulp &
paper industry in the Far East. We are excited about future growth
opportunities in the Asian pulp & paper industry and in other areas,
such as energy. Asia is a growing economy which will require
significant amounts of energy, so we see it as a key market for
Dyadic." Mr. Emalfarb continued, "This transaction, along with the
recently announced Debt-for-Equity conversion, significantly
simplifies and streamlines our balance sheet."
About Dyadic
Dyadic International, Inc. is engaged in the development,
manufacture and sale of biological products using a number of
proprietary fungal strains to produce enzymes and other biomaterials,
principally focused on a system for protein production based on the
patented Chrysosporium lucknowense fungus, known as C1. Dyadic
currently sells more than 45 liquid and dry enzyme products to more
than 200 industrial customers in approximately 50 countries.
Dyadic intends to utilize its patented enabling and proprietary
platform technologies on its own behalf and under license to business
collaborators for the discovery, development and manufacture of
biological products from genes to produce targeted protein products
for diverse markets.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements involve
risks and uncertainties that could cause our actual results,
performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of charge
on the SEC's web site at http://www.sec.gov, including our Annual
Report on Form 10-KSB for the year ended December 31, 2005. Except as
required by law, we expressly disclaim any intent or obligation to
update any forward-looking statements.